search
Back to results

Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial

Primary Purpose

Late Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Feeding; Difficult, Newborn

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Bovine colostrum
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Late Onset Neonatal Sepsis

Eligibility Criteria

24 Hours - 28 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • • Preterm Neonate having a gestational age equal or less than 34 weeks at birth, admitted in Ain-Shams University NICUs

Exclusion Criteria:

  • • Maternal risk factor of early onset sepsis, chorioamnionitis.

    • Proved early onset sepsis.
    • Life-threatening congenital abnormalities.
    • Inborn error of metabolism.
    • Chromosomal aberrations.
    • Neonates with underlying gastrointestinal problems (such as GIT anomalies) that prevent enteral feeding.
    • Perinatal asphyxia.

Sites / Locations

  • Medicin

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Non bovine colostrun

Bovine colostrum group

Arm Description

Preterm received preterm formula

Preterm received bovine colostrum as trophic feeding

Outcomes

Primary Outcome Measures

Incidence of Late Onset Sepsis in the three groups
Incidence of Late Onset Sepsis in the studied group measured by rodwell and tollner sepsis scoring system
The incidence of Necrotizing Enterocolitis in the three groups
Incidence of Necrotizing Enterocolitis in the three groups diagnosed according to bell's staging
The change of Active T regulatory cells In the three groups
Active T regulatory cells diagnosed by cell CD 4 expressing CD 25 high or simultaneously CD 25 plus FOXP3

Secondary Outcome Measures

Feeding intolerance is defined as presence of at least 3 consecutive days of any of the following:emesis, gastric residuals, diarrhea, blood in stools or abnormally enlarged bowel loops
Feeding intolerance
Neonatal mortality
Number of deaths in the study group
Duration of hospital stay
Duration of hospital stay

Full Information

First Posted
November 8, 2018
Last Updated
June 21, 2020
Sponsor
Ain Shams University
search

1. Study Identification

Unique Protocol Identification Number
NCT03926390
Brief Title
Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial
Official Title
Effect of Bovine Colostrum On T-Regulatory Cells, Prevention Of Late Onset Sepsis And Necrotizing Enterocolitis In Preterm Neonates
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
September 15, 2018 (Actual)
Primary Completion Date
June 15, 2019 (Actual)
Study Completion Date
September 15, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim was to assess the ability of bovine colostrum concentrate to reduce the incidence of late-onset sepsis episodes and necrotizing enterocolitis in artificially fed preterm neonates and its effect on T regulatory cells. And to evaluate the effect of bovine colostrum concentrate on feeding tolerance, growth, hospital stay and mortality in preterm neonates.
Detailed Description
The study was interventional, double blinded and randomized trial ، performed on preterm neonates( <34 week) admitted on Ain ShamsUniversity (ASU) neonatal intensive care units (NICU) after considering exclusion criteria. The enrolled patients was subdivided into two groups; group A are infants with non bovine colstrum and group B with bovine colostrum All infants received the standard neonatal care and underwent follow-up from birth until reach 37 week corrected gestational age, discharge or death whichever came first. I. Data Collection: Careful history taking Antenatal history including: rupture of membrane, Chorioamnionitis, history of urinary tract infection. Natal history including: mode of delivery, place of delivery, the need for resuscitation, recorded Apgar score at 1minute and 5 minutes. Postnatal history including: age of admission in neonatal intensive care unit, symptoms suggest infection. II. Thorough clinical assessment: Weight and Occiptofrontal circumference (twice weekly). Complete examination including cardiovascular, respiratory, abdominal and neurological examination. III. Laboratory investigations: Complete blood picture, C-reactive protein on admission and repeated twice weekly Blood culture before starting treatment and with any suspected sepsis. In first 24 hours and the end of second week : Collecting peripheral blood mononuclear cells to be analyzed for cellular parameters by flow cytometry (CD4 T cells, CD25 L, FOXP3). Three subsets of CD4+ T cells will be defined according to CD25 staining: CD25- , CD25 low, and CD25 high. Cells expressing CD25 high will be chosen and gated for the detection of FOXP3+ T cells. IV. Radiological investigations: Chest X-ray (It was done on admission and repeated when needed). Abdominal X-ray (when necrotizing enterocolitis is suspected). Abdominal ultrasound (when necrotizing enterocolitis is suspected). V. Follow-up and end-point of the study: All infant underwent follow-up from birth until reach 37 week corrected gestational age, discharge or death whichever came first.NPO for more than 24 hours The following primary outcome data was recorded: Clinical examination and laboratory investigations when clinically indicated for evidence of sepsis. Clinical examination and radiological investigations when clinically indicated for evidence of NEC. A secondary outcome measure includes weight increment per kg per week, duration of hospitalization, mortality if any, monitoring adverse effects of treatment (if any); such as emesis, increased gastric residuals, increased abdominal girth, diarrhea, skin rash. Long term outcome includes necrotizing enterocolitis, and intracranial hemorrhage.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Late Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Feeding; Difficult, Newborn

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Non bovine colostrun
Arm Type
No Intervention
Arm Description
Preterm received preterm formula
Arm Title
Bovine colostrum group
Arm Type
Active Comparator
Arm Description
Preterm received bovine colostrum as trophic feeding
Intervention Type
Dietary Supplement
Intervention Name(s)
Bovine colostrum
Intervention Description
bovine colostrum for first 2 weeks
Primary Outcome Measure Information:
Title
Incidence of Late Onset Sepsis in the three groups
Description
Incidence of Late Onset Sepsis in the studied group measured by rodwell and tollner sepsis scoring system
Time Frame
From time of randomization to discharge from nicu or death whichever comes first
Title
The incidence of Necrotizing Enterocolitis in the three groups
Description
Incidence of Necrotizing Enterocolitis in the three groups diagnosed according to bell's staging
Time Frame
From time of randomization to discharge from nicu or death whichever comes first
Title
The change of Active T regulatory cells In the three groups
Description
Active T regulatory cells diagnosed by cell CD 4 expressing CD 25 high or simultaneously CD 25 plus FOXP3
Time Frame
Change from base line at randomization and after intervention by 1 week
Secondary Outcome Measure Information:
Title
Feeding intolerance is defined as presence of at least 3 consecutive days of any of the following:emesis, gastric residuals, diarrhea, blood in stools or abnormally enlarged bowel loops
Description
Feeding intolerance
Time Frame
From time of randomization to discharge from nicu or death whichever comes first
Title
Neonatal mortality
Description
Number of deaths in the study group
Time Frame
From time of randomization to discharge from nicu or death whichever comes first
Title
Duration of hospital stay
Description
Duration of hospital stay
Time Frame
From time of randomization to discharge from nicu or death whichever comes first

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Hours
Maximum Age & Unit of Time
28 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: • Preterm Neonate having a gestational age equal or less than 34 weeks at birth, admitted in Ain-Shams University NICUs Exclusion Criteria: • Maternal risk factor of early onset sepsis, chorioamnionitis. Proved early onset sepsis. Life-threatening congenital abnormalities. Inborn error of metabolism. Chromosomal aberrations. Neonates with underlying gastrointestinal problems (such as GIT anomalies) that prevent enteral feeding. Perinatal asphyxia.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hisham Awad
Organizational Affiliation
professor of pediatrics Ain Shams university
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medicin
City
Giza
State/Province
Abasseya
ZIP/Postal Code
05000
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
research protocol

Learn more about this trial

Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial

We'll reach out to this number within 24 hrs